Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Clinical trial NCT02381080 · COMPLETED
Trial details
- NCT number
- NCT02381080
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-19
- Primary completion
- 2016-06-24
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.